← All trials
NCT01246440
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2010
- Primary completion
- Feb 1, 2014
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 39
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Español de Investigación en Cáncer de OvarioLead sponsor
- Universidad Autonoma de BarcelonaStudy chair
- Hospital Universitari Son DuretaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- Hospital Universitario Fundación AlcorcónOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- Neovii BiotechCollaborator
- Grupo Español de Investigación en Cáncer de OvarioReponsible party - principal investigator
- Corporacion Parc TauliOverall official - principal investigator
- University of Texas at HoustonStudy chair
- Universidad Autonoma de MadridOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.